In the rapidly changing and adjusting stock market, investors can often be drawn to stocks that have experienced a decline in price but remain actively traded. These resilient stocks present potential value investment opportunities, as their current market prices may not accurately reflect their intrinsic value. By identifying and analyzing these stocks, investors can capitalize on their potential for future growth and position themselves for potential returns as these stocks rebound in the market. Let's check out a few stocks that could fit the bill for a potential value play.
Epazz, Inc. (OTC: EPAZ)
EPAZ has emerged as an enticing value stock, attracting the attention of discerning investors. The company operates as a mission-critical provider of drone technology, blockchain mobile apps, and cloud-based business software solutions, offering a compelling investment opportunity with significant growth potential.
At the forefront of Epazz's innovative offerings is its subsidiary, ZenaDrone Inc. ZenaDrone has been making remarkable progress in the drone industry, establishing itself as a key player in the emerging drone-as-a-service market. Presently, the company is in negotiations with a financing institution to acquire up to 100 ZenaDrone 1000s, which will be utilized for drone services in Ireland. This development opens up exciting possibilities for ZenaDrone to provide comprehensive drone management and servicing solutions to Irish farmers, businesses, and government agencies.
The ZenaDrone 1000, equipped with advanced features and capabilities, is poised to revolutionize the agriculture industry. Its high-quality camera and autonomous flight capabilities enable users to capture breathtaking aerial photographs and videos, even in challenging weather conditions. With a multi-sensor system, the drone can precisely measure height, depth, vegetation, and GPS location, facilitating accurate monitoring of plant health and efficient weed spraying.
Beyond its agricultural applications, ZenaDrone's technology is gaining recognition in the military sector as well. The company has been invited to collaborate with the U.S. Air Force to conduct battlefield tests of the ZenaDrone 1000 platform, specifically for transporting life-saving blood to troops in the field. Such partnerships underscore the trust and confidence placed in ZenaDrone's capabilities.
EPAZ's focus extends beyond drone technology. In May, EPAZ announced the establishment of Galaxy Batteries Inc. as a repository for its intellectual property related to battery technology. With a strong emphasis on developing high-powered batteries for specialized devices and aircraft, Epazz is positioning itself to play a significant role in the rapidly evolving battery industry.
With its robust portfolio of innovative technologies, EPAZ offers a captivating value proposition for investors seeking exposure to the burgeoning drone and battery markets. As the company continues to expand its operations and secure strategic partnerships, it could have the potential to deliver substantial long-term returns.
Agrify Corp. (NASDAQ: AGFY) is a leading provider of advanced cultivation and extraction solutions in the cannabis industry. Their Vertical Farming Units (VFUs) offer controlled micro-environments, ensuring consistent yields and ROI at scale. Agrify's extraction product line includes hydrocarbon, ethanol, solventless, post-processing, and lab equipment, enabling producers to optimize extract quality and quantity.
On Friday, AGFY closed at $0.19 per share, reflecting a 0.21% increase. Agrify recently announced significant developments that highlight their commitment to innovation and market leadership. They introduced the Diamond Miner, a revolutionary product under their solvent extraction brand, Precision Extraction Solutions. This cutting-edge solution facilitates safe and consistent THC-A crystallization for premium concentrates.
Precision Extraction Solutions, acquired by Agrify in October 2021, is renowned for its comprehensive, solvent-based extraction and post-processing solutions. The Diamond Miner, with a 1.3-liter capacity, eliminates mason jars, ensuring safety and consistency. Featuring a liquid jacketed vessel for precise temperature control, it maintains a consistent internal environment.
Agrify prioritizes safety and compliance, evident in the Diamond Miner's Technical Report certification by Pressure Safety Inspectors (PSI). Constructed with premium stainless steel and 2 sight glasses for easy inspection, it enhances production efficiency.
Another significant release by Agrify is the industry-first Hydrocarbon Distillation Unit (HDU) under Precision Extraction Solutions. This versatile unit continuously distills the hydrocarbon solvent, enhancing operational efficiency and reducing contamination. It can be used independently or integrated into existing systems, showcasing Agrify's end-to-end extraction solutions.
The HDU, positioned between the solvent tank and the extractor, prevents contamination during extraction. Operators can refill the solvent tank and distill continuously, resulting in higher extraction cycles per day and improved productivity.
Through innovative products like the Diamond Miner and HDU, Agrify remains at the forefront of extraction technology, offering efficient solutions to achieve production goals. Their dedication extends beyond equipment, encompassing service support, training, and expert advice. Agrify's Hydrocarbon Distillation Unit is compatible with various hydrocarbon processing equipment, establishing them as a key player in the cannabis industry.
Propanc Biopharma, Inc. (OTC: PPCB) is a biopharmaceutical company developing innovative cancer treatments for patients with recurrent and metastatic cancer, with a specific focus on pancreatic, ovarian, and other solid tumors. The company's approach involves using pancreatic proenzymes to target and eliminate cancer stem cells, which are widely recognized as playing a crucial role in tumor recurrence and metastasis.
Propanc's lead product candidate, PRP, is a specialized blend of pancreatic proenzymes designed to selectively target and eradicate cancer stem cells in pancreatic, ovarian, and various other types of cancers. By leveraging the body's inherent defense mechanisms, Propanc aims to disrupt the mechanisms that lead to tumor recurrence and metastasis, ultimately improving patient outcomes.
In recent news, Propanc experienced a notable surge in its stock performance on Friday. The stock price of PPCB closed at $0.1350, reflecting a remarkable increase of $0.0701 or 108.01%. This significant upswing in share price demonstrates growing investor interest and confidence in the company's potential and strategic direction.
PRP offers a groundbreaking therapeutic approach that specifically targets cancer stem cells while minimizing the undesirable side effects often associated with conventional treatment options. As a result, Propanc's unique strategy has garnered attention from investors seeking innovative solutions for metastatic cancer treatment.
Moreover, PPCB has made noteworthy achievements in expanding its intellectual property portfolio, with patents granted for the composition of PRP and the method to treat cancer stem cells. These milestones solidify the company's position in the market and provide a foundation for future growth and potential collaborations.
Propanc's ongoing research collaborations with leading universities also contribute to its growth trajectory. These partnerships aim to develop a synthetic recombinant proenzyme formulation as a backup clinical compound to PRP and explore additional potential applications of this groundbreaking therapy.
With its recent stock performance surge and promising advancements, PPCB represents an emerging stock that has the potential to deliver future value to investors.
Bluejay Diagnostics, Inc. (NASDAQ: BJDX) is a medical diagnostics company that offers potential value investment opportunities in the ever-changing stock market.
BJDX is committed to improving patient outcomes in critical care settings through the development of rapid tests using whole blood on its Symphony platform. The Symphony System is designed to provide quantitative measurements of specific biomarkers, enabling healthcare professionals to make informed decisions regarding patient care and monitoring in a timely manner. Clinical studies have validated the potential of Symphony to deliver laboratory-quality results rapidly, with the Symphony IL-6 data affirming its capabilities.
In its financial report for the first quarter ended March 31, 2023, Bluejay Diagnostics highlighted key aspects of its performance. The company reported cash and cash equivalents of $6.8 million, compared to $10.1 million at the end of December 2022. Bluejay is actively managing its cash burn during the FDA submission process while closely monitoring its liquidity.
Research and development expenses for the quarter were approximately $1.4 million, representing an increase compared to the same period in 2022. The rise was primarily due to higher personnel costs and expenses related to clinical trials. Bluejay expects future research and development expenses to be focused on supporting its regulatory strategy and potential manufacturing improvements.
General and administrative expenses for the quarter amounted to approximately $1.2 million, showing a slight decrease compared to the same period in 2022. The company has taken measures to preserve capital by limiting infrastructure investment in line with its commercialization timeline. Bluejay intends to optimize operational alignment by monitoring and reducing general and administrative spending as necessary.
Sales and marketing expenses for the quarter were approximately $148,000, an increase from the comparable period in 2022. However, Bluejay anticipates minimal sales and marketing efforts in 2023, aligning its expenditure with the goal of bringing the Symphony System to the market.
Bluejay Diagnostics reported a net loss of $2.5 million, or $0.12 per share, for the first quarter of 2023, compared to a net loss of $2.0 million, or $0.10 per share, for the same period in 2022.
Disclaimers:CapitalGainsReport (CGR) is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. CapitalGainsReport (CGR) is owned by RazorPitch Inc. and has been retained by Epazz Inc. to assist in the production and distribution of content. 'CGR' is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by CapitalGainsReport/RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. CGR/RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Please visit CapitalGainsReport.com/Disclaimer for full disclaimer.
CONTACT: CapitalGainsReport
Mark McKelvie
Editor
Markrmckelvie@gmail.com
585-301-7700
.
EPAZZ, INC. 
